The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Pharmaceutical Contract Manufacturing Market by business segment (API and FDF), type of API (branded and generic), type of FDF (oral solids, parenteral and others), type of packaging form (blisters, bottles, injectables and others), scale of operation (clinical and commercial), end-users and key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle-East and North Africa): Industry Trends and Global Forecasts (3rd Edition), 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    July 2021

  • Pages
    545

  • View Count
    11489

Example Insights

Pharmaceutical-Contract-Manufacturing-Market-Context Pharmaceutical-Contract-Manufacturing-Market-Example-highlights Pharmaceutical-Contract-Manufacturing-Market-List-of-Pharmaceutical-CMOs Pharmaceutical-Contract-Manufacturing-Market-Distribution-by-Company-Size-and-HQ
Pharmaceutical-Contract-Manufacturing-Market-Geographical-Distribution Pharmaceutical-Contract-Manufacturing-Market-Recent-Expansions Pharmaceutical-Contract-Manufacturing-Market-Capacity-Analysis Pharmaceutical-Contract-Manufacturing-Market-Current-and-Future-Demand
Pharmaceutical-Contract-Manufacturing-Market-Mergers-and-Acquisitions Pharmaceutical-Contract-Manufacturing-Market-Distribution-by-Scale-of-Operation Pharmaceutical-Contract-Manufacturing-Market-Opportunity  

 

Overview

At present, the pharmaceutical industry is dominated by the presence of small molecule products, which represent close to 80% of the overall pipeline. Even though biologics have shown significant promise in the treatment of a wide range of disorders, in recent years, approval of novel small molecules has been on the rise. In fact, in 2020, over 50 small molecule drugs were approved by the US FDA, while around 8,000 such candidates are being evaluated across different stages of development. It is worth mentioning that the pipeline features increasingly complex candidates, which require specialized facilities, advanced equipment and operational expertise. As setting-up / acquiring manufacturing capabilities is both time and cost intensive process, it is extremely challenging for pharmaceutical companies to perform development and manufacturing operations independently. The aforementioned constraints, coupled to the rising demand for safer and effective drugs (currently driven by the COVID-19 pandemic), have prompted players to outsource a significant portion of their business segments to contract manufacturing organizations (CMOs), and contract development and manufacturing organizations (CDMOs).

The current landscape of pharmaceutical contract service providers is highly fragmented, featuring a mix of start-ups, mid-sized firms and established players. The inherent expertise of CMOs and CDMOs is believed to be capable of enabling reduction in the time-to-market a product, significant cost-benefits, as well as access to larger production capacities and novel technologies.  It is worth mentioning that there has been substantial merger and acquisition activity in the pharmaceutical contract manufacturing market in the past few years, as players strive to become one stop shops, in order to cater to the diverse needs of pharmaceutical developers (ranging from early-stage development to commercial production). Considering the ongoing innovation in production technologies, evolving pipeline of small molecule products and the increasing demand for such drug candidates, we believe that the pharmaceutical contract manufacturing market is likely to witness positive growth in the coming years.

Scope of the Report

The “Pharmaceutical Contract Manufacturing Market (3rd Edition) Distribution by key business segments (API(s) and FDF(s)), type of API(s) manufactured (branded and generic), type of FDF(s) offered (oral solids, parenteral and others), type of primary packaging form (blisters, bottles, injectables and others), scale of operation (clinical and commercial), type of end-users (small pharmaceutical companies, mid-sized pharmaceutical companies and large pharmaceutical companies) and key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa: Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing industry. Amongst the other elements, the report features:

  • A detailed overview of the overall market landscape, featuring an elaborate list of over 450 active CMOs engaged in this domain, along with information on several relevant parameters, such as year of establishment, company size, geographical location of CMOs, type of business segment (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of API(s) manufactured (complex, generic and sterile), type of FDF(s) offered (oral solids, liquids / semi-solids, injectables, inhalation and others), type of service(s) offered, type of primary packaging form (blister, tubes, vial / cartridge, ampoule, sachets / pouches / bags, inhalers / nasal sprays, glass / plastic / dropper bottles, pre-filled syringes / autoinjectors), scale of operation (preclinical, clinical and commercial) and specific location of manufacturing facilities (country-wise).
  • A detailed analysis of various mergers and acquisitions that have taken place in this domain, highlighting the trend in number of companies acquired and geographical distribution of the activity, during the period 2017-2021. Further, it highlights the relationship between deal multiples (based on revenues), number of employees and experience of the acquired firm. 
  • A detailed analysis of the recent expansions (since 2017) undertaken by various service providers in order to augment their respective pharmaceutical contract manufacturing service portfolios, based on a several relevant parameters, such as year of expansion, purpose of expansion (capability expansion, capacity expansion, facility expansion, new facility), type of business segment (API(s), FDF(s)), capital invested, scale of operation (clinical, commercial), type of service(s) offered (formulation, manufacturing, packaging), geographical location of facility, and most active players (in terms of number of instances).
  • An estimate of the global, installed capacity for the manufacturing of small-molecule drugs, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe and Asia Pacific).
  • Informed estimates of the annual clinical and commercial demand for small molecule drugs, across key geographical regions.
  • A detailed analysis of pharmaceutical contract manufacturing service providers’ capabilities in different regions, based on several relevant parameters, such as type of business segment, type of service(s) offered and type of packaging form.
  • A detailed analysis of various pharmaceutical contract manufacturing service providers featuring schematic representations, including [A] a heat map analysis, highlighting the distribution of integrated contract service providers (companies offering manufacturing services for both small and large molecules), on the basis of  location of their headquarters, year of establishment and number of employees, [B] a geographical landscape analysis, highlighting CMOs that have a wide geographical reach, on the basis of their presence (manufacturing facilities) across various regions, and [C] a grid representation, highlighting the global and regional trend of API and FDF outsourcing services, based on the location of headquarters of the company, number of employees, type of business segment, type of service(s) offered and scale of operation. 
  • A detailed discussion on various guidelines laid down by major regulatory bodies, across different countries, featuring an elaborative assessment of over 450 CMOs engaged in this domain, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. Additionally, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies.
  • Elaborate profiles of key players engaged in offering pharmaceutical contract manufacturing services. Each profile features a brief overview of the company, along with information on its financial performance (if available), service(s) portfolio, manufacturing facilities and capabilities, recent developments and an informed future outlook.
  • A case study highlighting a comparison of the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes.
  • A qualitative analysis highlighting the various factors that need to be taken into consideration by pharmaceutical drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A detailed analysis capturing the key parameters and trends that are likely to influence the future of the pharmaceutical contract manufacturing market, under an elaborate SWOT framework. Further, it presents a schematic Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall pharmaceutical industry.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market based on several parameters, such as growth of the overall pharmaceutical market, cost of goods sold, direct manufacturing costs. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. The report also features the likely distribution of the opportunity across [A] key business segments (API(s) and FDF(s)), [B] type of API(s) manufactured (branded and generic), [C] type of FDF(s) offered (oral solids, parenteral and others), [D] type of primary packaging form (blisters, bottles, injectables and others), [E] scale of operation (clinical and commercial), [F] type of end-users (small pharmaceutical companies, mid-sized pharmaceutical companies and large pharmaceutical companies) and [G] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa. In order to account for future uncertainties and add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Scott Goldstein (Ex - Director, Business Development, Ajinomoto Bio-Pharma Services)
  • Thomas Früh (Ex - CEO, Bachem)
  • Bhaskar Venepalli (President and CEO, CiVentiChem)
  • Roberto Margarita (Director, Business Development, CordenPharma)
  • Allison Vavala (Director, Commercial Development, Helsinn Group)
  • Kevin Daley (Director, Pharmaceuticals Marketing, Novasep)
  • Piyush Desai (Director, Operations, Sovereign Pharma)
  • Ilan Avni (Vice President Business Development, Marketing, and IP, Wavelength Pharmaceuticals)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players engaged in offering contract manufacturing services for small molecules?
  • What are the key value drivers of the merger and acquisition activity observed within the pharmaceutical contract manufacturing industry?
  • What are the different expansion initiatives undertaken by pharmaceutical contract manufacturers in the recent past?
  • Which regions represent the current key contract manufacturing hubs for small molecules?What is the current, installed capacity for contract manufacturing of small molecules?
  • What is the current, global demand for small molecules? How is the demand for such candidates likely to evolve in the foreseen future?    
  • What percentage of the pharmaceutical manufacturing operations are presently outsourced?
  • What factors should be taken into consideration while deciding whether the manufacturing operations for small molecules should be kept in-house or outsourced?
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the pharmaceutical contract manufacturing market in the mid-long term.

Chapter 3 provides a general introduction to various type of manufacturers engaged in the pharmaceutical market. It further includes a brief overview of the concept of contract manufacturing, featuring a discussion on the evolution of contract services in this industry. Additionally, it highlights details related to the need for outsourcing in this domain. Further, the chapter includes a brief overview of contract manufacturing models that have been adopted in the pharmaceutical industry and an exhaustive list of services offered by CMOs; the chapter concludes with a discussion on the challenges associated with the outsourcing of pharmaceutical manufacturing operations.

Chapter 4 features a detailed discussion on various guidelines laid down by major regulatory bodies, across different countries, featuring an elaborative assessment of over 450 CMOs engaged in this domain, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. Additionally, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies

Chapter 5 provides a detailed overview of the overall market landscape, featuring an elaborate list of over 450 active CMOs engaged in this domain, along with information on several relevant parameters, such as year of establishment, company size, geographical location of CMOs, type of business segment (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of API(s) manufactured (complex, generic and sterile), type of FDF(s) offered (oral solids, liquids / semi-solids, injectables, inhalation and others), type of service(s) offered, type of primary packaging form (blister, tubes, vial / cartridge, ampoule, sachets / pouches / bags, inhalers / nasal sprays, glass / plastic / dropper bottles, pre-filled syringes / autoinjectors), scale of operation (preclinical, clinical and commercial) and specific location of manufacturing facilities (country-wise). 

Chapter 6 presents a detailed analysis of pharmaceutical contract manufacturing service providers’ capabilities in different regions, based on several relevant parameters, such as type of business segment, type of service(s) offered and type of packaging form.

Chapter 7 features elaborate profiles of key players engaged in offering pharmaceutical contract manufacturing services. Each profile features a brief overview of the company, along with information on its financial performance (if available), service(s) portfolio, manufacturing facilities and capabilities, recent developments and an informed future outlook.

Chapter 8 presents a qualitative analysis highlighting the various factors that need to be taken into consideration by pharmaceutical drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

Chapter 9 presents a detailed analysis of various mergers and acquisitions that have taken place in this domain, highlighting the trend in number of companies acquired and geographical distribution of the activity, during the period 2017-2021. Further, it highlights the relationship between deal multiples (based on revenues), number of employees and experience of the acquired firm.

Chapter 10 features A detailed analysis of the recent expansions (since 2017) undertaken by various service providers in order to augment their respective pharmaceutical contract manufacturing service portfolios, based on a several relevant parameters, such as year of expansion, purpose of expansion (capability expansion, capacity expansion, facility expansion, new facility), type of business segment (API(s), FDF(s)), capital invested, scale of operation (clinical, commercial), type of service(s) offered (formulation, manufacturing, packaging), geographical location of facility, and most active players (in terms of number of instances).

Chapter 11 features an estimate of the global, installed capacity for the manufacturing of small-molecule drugs, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe and Asia Pacific). Overall, the analysis represents a holistic view of the supply-side of the market, allowing us to present an informed opinion on whether the present capacity will be able to meet the likely future demand.

Chapter 12 provides informed estimates of the annual clinical and commercial demand for small molecule drugs, across key geographical regions, based on relevant parameters, such as number of patient population, dosage and dose frequency. 

Chapter 13 represents a detailed market forecast, highlighting the future potential of the pharmaceutical contract manufacturing market, till 2030. Additionally it features the likely distribution of the opportunity across different [A] key business segments (API(s) and FDF(s)), [B] type of API(s) manufactured (branded and generic), [C] type of FDF(s) offered (oral solids, parenteral and others), [D] type of primary packaging form (blisters, bottles, injectables and others), [E] scale of operation (clinical and commercial), [F] type of end-users (large pharmaceutical companies, mid-sized pharmaceutical companies and small pharmaceutical companies) and [G] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa.

Chapter 14 presents a detailed analysis of various pharmaceutical contract manufacturing service providers featuring schematic representations, including [A] a heat map analysis, highlighting the distribution of integrated contract service providers (companies offering manufacturing services for both small and large molecules), on the basis of  location of their headquarters, year of establishment and number of employees, [B] a geographical landscape analysis, highlighting CMOs that have a wide geographical reach, on the basis of their presence (manufacturing facilities) across various regions, and [C] a grid representation, highlighting the global and regional trend of API and FDF outsourcing services, based on the location of headquarters of the company, number of employees, type of business segment, type of service(s) offered and scale of operation. 

Chapter 15 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the pharmaceutical contract manufacturing market, under an elaborate SWOT framework. Further, it presents a schematic Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall pharmaceutical industry.

Chapter 16 is a case study highlighting a comparison of the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes.

Chapter 17 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 18 is a collection of executive insight(s) of the discussion(s) that were held with key stakeholder(s) in this market. We have presented details of interviews held with Scott Goldstein (Ex - Director, Business Development, Ajinomoto Bio-Pharma Services), Thomas Früh (Ex - CEO, Bachem), Bhaskar Venepalli (President and CEO, CiVentiChem), Roberto Margarita (Director, Business Development, CordenPharma), Allison Vavala (Director, Commercial Development, Helsinn Group), Kevin Daley (Director, Pharmaceuticals Marketing, Novasep), Piyush Desai (Director, Operations, Sovereign Pharma), Ilan Avni (Vice President Business Development, Marketing, and IP, Wavelength Pharmaceuticals).

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 20 is an appendix, which provides the list of companies and organizations included in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Manufacturers 
3.3. Overview of Pharmaceutical Contract Manufacturing 
3.4. Evolution of Pharmaceutical Contract Manufacturing 
3.4.1. Traditional Pharmaceutical CMOs
3.4.2. Modern Pharmaceutical CMOs
3.5. Need for Outsourcing in the Pharmaceutical Industry
3.6. Recent Trends in the Pharmaceutical Contract Manufacturing Industry
3.6.1. Tactical Partnerships
3.6.2. Integrated End-to-End Business Model
3.6.3. Software Service Providers
3.7. Services Offered by CMOs
3.8. Key Considerations While Selecting a CMO Partner
3.9. Risks and Challenges Associated with Outsourcing Pharmaceutical Manufacturing Operations

4. REGULATORY LANDSCAPE FOR PHARMACEUTICAL CONTRACT MANUFACTURERS
4.1. Chapter Overview
4.2. Regulatory Guidelines in North America
4.2.1. The US Scenario
4.2.2. Canadian Scenario
4.3. Regulatory Guidelines in Europe

4.4. Regulatory Guidelines in Asia-Pacific and Rest of the World
4.4.1. Chinese Scenario
4.4.2. Indian Scenario
4.4.3. Japanese Scenario
4.4.4. South Korean Scenario
4.4.5 Australian Scenario
4.4.6. Brazilian Scenario
4.5. Analysis of Pharmaceutical CMOs by Approval Received from Regulatory Authorities
4.6. Regional Summary of Regulatory Scenario (Bubble Analysis) 

5. PHARMACEUTICAL CMOs: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Pharmaceutical CMOs: List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Business Segment
5.2.5. Analysis by Type of API Manufactured
5.2.6. Analysis by Type of FDF Offered
5.2.7. Analysis by Type of Molecule
5.2.8. Analysis by Type of Service(s) Offered
5.2.9. Analysis by Type of Primary Packaging Form Offered 
5.2.10. Analysis by Scale of Operation
5.2.11. Analysis by Location of Manufacturing Facility
5.2.11.1 Pharmaceutical Contract Manufacturing Facilities in North America
5.2.11.2 Pharmaceutical Contract Manufacturing Facilities in Europe
5.2.11.3 Pharmaceutical Contract Manufacturing Facilities in Asia-Pacific and Rest of the World

6. REGIONAL CAPABILITY
6.1. Chapter Overview
6.2. Key Assumptions and Methodology
6.3. Regional Capability Analysis of Pharmaceutical CMOs
6.3.1 Analysis of CMOs based in North America
6.3.2. Analysis of CMOs based in Europe
6.3.3. Analysis of CMOs based in Asia-Pacific and Rest of the World

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Key Benefits Key Benefits Offered by the One-Stop-Shop Model 
7.3 Profiles of Players Operating as One-Stop-Shops

7.4. North America
7.4.1. AMRI Global
7.4.1.1. Company Overview
7.4.1.2. Service Portfolio
7.4.1.3. Manufacturing Capabilities and Facilities
7.4.1.4. Recent Developments and Future Outlook

7.4.2. Altasciences
7.4.2.1. Company Overview
7.4.2.2. Service Portfolio
7.4.2.3. Manufacturing Capabilities and Facilities
7.4.2.4. Recent Developments and Future Outlook

7.4.3. Cambrex
7.4.3.1. Company Overview
7.4.3.2. Service Portfolio
7.4.3.3. Manufacturing Capabilities and Facilities
7.4.3.4. Recent Developments and Future Outlook

7.4.4. Catalent
7.4.4.1. Company Overview
7.4.4.2. Financial Information
7.4.4.3. Service Portfolio
7.4.4.4. Manufacturing Capabilities and Facilities
7.4.4.5. Recent Developments and Future Outlook

7.4.5. DPT Laboratories
7.4.5.1. Company Overview
7.4.5.2. Service Portfolio
7.4.5.3. Manufacturing Capabilities and Facilities
7.4.5.4. Recent Developments and Future Outlook

7.4.6. Thermo Fisher Scientific
7.4.6.1. Company Overview
7.4.6.2. Financial Information
7.4.6.3. Service Portfolio
7.4.6.4. Manufacturing Capabilities and Facilities
7.4.6.5. Recent Developments and Future Outlook

7.5. Europe
7.5.1. Aenova Group
7.5.1.1. Company Overview
7.5.1.2. Financial Information
7.5.1.3. Service Portfolio
7.5.1.4. Manufacturing Capabilities and Facilities
7.5.1.5. Recent Developments and Future Outlook

7.5.2. Almac 
7.5.2.1. Company Overview
7.5.2.2. Service Portfolio
7.5.2.3. Recent Developments and Future Outlook

7.5.3. Corden Pharma
7.5.3.1. Company Overview
7.5.3.2. Service Portfolio
7.5.3.3. Manufacturing Capabilities and Facilities
7.5.3.4. Recent Developments and Future Outlook

7.5.4. Fresenius Kabi
7.5.4.1. Company Overview
7.5.4.2. Financial Information
7.5.4.3. Service Portfolio
7.5.4.4. Manufacturing Capabilities and Facilities
7.5.4.5. Recent Developments and Future Outlook

7.5.5. Glatt
7.5.5.1. Company Overview
7.5.5.2. Service Portfolio
7.5.5.3. Manufacturing Capabilities and Facilities
7.5.5.4. Recent Developments and Future Outlook

7.5.6. Hovione
7.5.6.1. Company overview
7.5.6.2. Service Portfolio
7.5.6.3. Manufacturing Capabilities and Facilities
7.5.6.4. Recent Developments and Future Outlook

7.5.7. Recipharm
7.5.7.1. Company Overview
7.5.7.2. Financial Information
7.5.7.3. Service Portfolio
7.5.7.4. Manufacturing Capabilities and Facilities
7.5.7.5. Recent Developments and Future Outlook

7.5.8. Siegfried
7.5.8.1. Company Overview
7.5.8.2. Financial Information
7.5.8.3. Service Portfolio
7.5.8.4. Manufacturing Capabilities and Facilities
7.5.8.5. Recent Developments and Future Outlook

7.6. Asia-Pacific and Rest of the World
7.6.1. CMIC Group
7.6.1.1. Company Overview
7.6.1.2. Financial Information
7.6.1.3. Service Portfolio
7.6.1.4. Recent Developments and Future Outlook

7.6.2. Nectar Lifesciences
7.6.2.1. Company Overview
7.6.2.2. Financial Information
7.6.2.3. Service Portfolio
7.6.2.4. Manufacturing Capabilities and Facilities
7.6.2.5. Recent Developments and Future Outlook

7.6.3. Syngene
7.6.3.1. Company Overview
7.6.3.2. Financial Information
7.6.3.3. Service Portfolio
7.6.3.4. Manufacturing Capabilities and Facilities
7.6.3.5. Recent Developments and Future Outlook

7.6.4. WuXi AppTec
7.6.4.1. Company Overview
7.6.4.2. Financial Information
7.6.4.3. Service Portfolio
7.6.4.4. Manufacturing Capabilities and Facilities
7.6.4.5. Recent Developments and Future Outlook

8. MAKE VERSUS BUY DECISION FRAMEWORK
8.1. Chapter Overview
8.2. Assumptions and Key Parameters 
8.3. Pharmaceutical Contract Manufacturers: Make versus Buy Decision Making
8.3.1. Scenario 1
8.3.2. Scenario 2
8.3.3. Scenario 3
8.3.4. Scenario 4
8.4. Concluding Remarks

9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models
9.3. Pharmaceutical Contract Manufacturing: Mergers and Acquisitions 
9.3.1. Cumulative Year-wise Trend
9.3.2. Analysis by Type of Agreement 
9.3.3. Analysis by Type of Acquisition 
9.3.4. Analysis by Focus Area 
9.3.5. Analysis by Type of Business Segment 
9.3.6. Analysis by Type of Service(s) Offered
9.3.7. Analysis by Scale of Operation 
9.3.8. Analysis by Geography
9.3.9. Analysis by Location of Manufacturing Facility
9.3.10. Most Active Acquirers: Analysis by Number of Acquisitions
9.3.11. Analysis by Key Value Drivers
9.3.11.1. Analysis by Year of Acquisition and Key Value Drivers
9.4. Key Acquisitions: Analysis by Deal Multiples

10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Pharmaceutical Contract Manufacturing Market: Expansions
10.2.1. Cumulative Year-wise Distribution
10.2.2. Analysis by Purpose of Expansion
10.2.3. Analysis by Year and Purpose of Expansion
10.2.4. Analysis by Type of Business Segment
10.2.5. Analysis by Type of Molecule
10.2.6. Analysis by Type of Service(s) Offered
10.2.7. Analysis by Scale of Operation
10.2.8. Analysis by Capital Invested
10.2.9. Analysis by Location of Headquarters
10.2.10. Analysis by Purpose of Expansion and Location of Headquarters
10.2.11. Analysis by Location of Manufacturing Facility
10.2.12. Most Active Players: Analysis by Number of Recent Expansions

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Pharmaceutical Contract Manufacturing: Global Production Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Location of Headquarters
11.3.3.1. Analysis of Capacity Installed in North America
11.3.3.2. Analysis of Capacity Installed in Europe
11.3.3.3. Analysis of Capacity Installed in Asia-Pacific
11.4. Concluding Remarks

12. DEMAND ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Overall Annual Demand for Small Molecule APIs, 2021-2030
12.3.1. Analysis by Scale of Operation
12.4. Correlation Between Annual Demand and Capacity

13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Pharmaceutical Contract Manufacturing Market, 2021-2030
13.3.1. Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Business Segment
13.1.2. Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of API Manufactured
13.1.3. Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of FDF Offered
13.1.4. Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Scale of Operation
13.1.5. Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of Packaging Form
13.1.6. Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of End-Users
13.1.7. Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Geography

13.1.7.1. Pharmaceutical Contract Manufacturing Market in North America, 2021-2030
13.1.7.1.1. Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Business Segment
13.1.7.1.2. Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of API Manufactured
13.1.7.1.3. Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of FDF Offered
13.1.7.1.4. Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Scale of Operation
13.1.7.1.5. Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of Packaging Form
13.1.7.1.6. Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of End-Users

13.1.7.2. Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030
13.1.7.2.1. Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Business Segment
13.1.7.2.2. Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of API Manufactured
13.1.7.2.3. Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of FDF Offered
13.1.7.2.4. Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Scale of Operation
13.1.7.2.5. Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of Packaging Form
13.1.7.2.6. Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of End-Users

13.1.7.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030
13.1.7.3.1. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Business Segment
13.1.7.3.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of API Manufactured
13.1.7.3.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of FDF Offered
13.1.7.3.4. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
13.1.7.3.5. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of Packagiey value ng Form
13.1.7.3.6. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of End-Users

13.1.7.4. Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030
13.1.7.4.1. Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Business Segment
13.1.7.4.2. Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of API Manufactured
13.1.7.4.3. Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of FDF Offered
13.1.7.4.4. Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Scale of Operation
13.1.7.4.5. Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of Packaging Form
13.1.7.4.6. Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of End-Users

13.1.7.5. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030
13.1.7.5.1. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Business Segment
13.1.7.5.2. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of API Manufactured
13.1.7.5.3. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of FDF Offered
13.1.7.5.4. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Scale of Operation
13.1.7.5.5. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of Packaging Form
13.1.7.5.6. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of End-Users

14. KEY INSIGHTS
14.1. Chapter Overview
14.2. Integrated Contract Service Providers (Heat Map Analysis)
14.3. Analysis by Geography 
14.4. Analysis by Geography, Company Size and Business Segment

15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Strengths
15.3. Weaknesses
15.4. Opportunities
15.5. Threats
15.6. Comparison of SWOT Factors

16. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES DRUGS / THERAPIES
16.1. Chapter Overview
16.2. Small Molecule and Large Molecule Drugs / Therapies
16.2.1. Comparison of General Characteristics
16.2.2. Comparison of Key Specifications
16.2.3. Comparison of Manufacturing Processes
16.2.4. Comparison of Key Manufacturing-related Challenges

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Ajinomoto Althea
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Scott Goldstein, Ex - Director, Business Development, Drug Product Manufacturing

18.3. Bachem
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Thomas Fruh, Ex - Chief Executive Officer

18.4. CiVentiChem
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Bhaskar VenePalli, President and Chief Executive Officer

18.5. CordenPharma
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Roberto Margartia, Director, Business Development

18.6. Helsinn Group
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Allison Vavala, Director, Commercial Development

18.7. Novasep
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Kevin Daley, Director, Pharmaceuticals Marketing

18.8. Sovereign Pharma
18.8.1. Company Snapshot
18.8.2. Interview Transcript: Piyush Desai, Director, Operations

18.9. Wavelength Pharmaceuticals
18.9.1. Company Snapshot
18.9.2. Interview Transcript: Ilan Avni, Vice President Business Development, Marketing, and IP

19. APPENDIX I: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Type of Contract Manufacturers
Figure 3.2 Types of Third-Party Service Providers in the Pharmaceutical Contract Manufacturing Industry
Figure 3.3 Outsourcing across Various Components of Pharmaceutical Value Chain
Figure 3.4 Services Offered by CMOs
Figure 3.5 Key Considerations While Selecting a CMO Partner
Figure 4.1 Key Regulatory Requirements for CMOs and CROs in India
Figure 4.2 Regulatory Landscape for Pharmaceutical CMOs: Distribution by Types of Regulatory Authorities
Figure 4.3 Bubble Analysis: Regional Regulatory Summary
Figure 5.1 Pharmaceutical CMOs: Distribution by Year of Establishment
Figure 5.2 Pharmaceutical CMOs: Distribution by Company Size
Figure 5.3 Pharmaceutical CMOs: Distribution by Location of Headquarters
Figure 5.4 Pharmaceutical CMOs: Distribution by Type of Business Segment
Figure 5.5 Pharmaceutical CMOs: Distribution by Type of API Manufactured
Figure 5.6 Pharmaceutical CMOs: Distribution by Type of FDF Offered
Figure 5.7 Pharmaceutical CMOs: Distribution by Type of Molecule
Figure 5.8 Pharmaceutical CMOs: Distribution by Type of Service(s) Offered
Figure 5.9 Pharmaceutical CMOs: Distribution by Type of Primary Packaging Offered
Figure 5.10 Pharmaceutical CMOs: Distribution by Scale of Operation
Figure 5.11 Pharmaceutical CMOs: Distribution by Location of Headquarters and Type of Service(s) Offered
Figure 5.12 Pharmaceutical CMOs: Distribution by Type of Business Segment and Type of Service(s) Offered
Figure 5.13 Pharmaceutical CMOs: Distribution by Type of Service(s) Offered and Scale of Operation
Figure 5.14 Pharmaceutical CMOs: Distribution of Manufacturing Facilities in North America
Figure 5.15 Pharmaceutical CMOs: Distribution of Manufacturing Facilities in Europe
Figure 5.16 Pharmaceutical CMOs: Distribution of Manufacturing Facilities in Asia-Pacific and Rest of the World
Figure 6.1 Regional Distribution of Pharmaceutical Contract Manufacturing Facilities in North America
Figure 6.2 Regional Distribution of Pharmaceutical Contract Manufacturing Facilities in Europe
Figure 6.3 Regional Distribution of Pharmaceutical Contract Manufacturing Facilities in Asia-Pacific and Rest of the World
Figure 7.1 AMRI: Service Portfolio
Figure 7.2 Altasciences: Service Portfolio
Figure 7.3 Cambrex: Service Portfolio
Figure 7.4 Catalent: Annual Revenues, 2014-2020 (USD Million)
Figure 7.5 Catalent: Service Portfolio
Figure 7.6 DPT Laboratories: Service Portfolio
Figure 7.7 Thermo Fisher Scientific: Annual Revenues, 2014-2020 (USD Billion)
Figure 7.8 Thermo Fisher Scientific: Revenues by Business Segments, 2020 (USD Billion)
Figure 7.9 Thermo Fisher Scientific: Service Portfolio
Figure 7.10 Aenova Group: Annual Revenues 2017-2019 (EUR Million)
Figure 7.11 Aenova Group: Service Portfolio
Figure 7.12 Almac Group: Service Portfolio
Figure 7.13 Corden Pharma: Service Portfolio
Figure 7.14 Fresenius Kabi: Annual Revenues, 2014-2020 (EUR Million)
Figure 7.15 Fresenius Kabi: Revenues by Product Segments, 2020 (EUR Million)
Figure 7.16 Fresenius Kabi: Service Portfolio
Figure 7.17 Glatt: Service Portfolio
Figure 7.18 Hovione: Service Portfolio
Figure 7.19 Recipharm: Annual Revenues, 2014-2020 (SEK Million)
Figure 7.20 Recipharm: Revenues by Business Segment, 2020 (SEK Million)
Figure 7.21 Recipharm: Service Portfolio
Figure 7.22 Siegfried: Annual Revenues, 2013-2020 (CHF Million)
Figure 7.23 Siegfried: Revenues by Product Segments, 2020 (CHF Million)
Figure 7.24 Siegfried: Service Portfolio
Figure 7.25 CMIC Group: Annual Revenues, 2014 - H1 2021 (JPY Billion)
Figure 7.26 CMIC Group: Revenues by Business Segment, 2020 (JPY Billion)
Figure 7.27 CMIC Group: Service Portfolio
Figure 7.28 Nectar Lifesciences: Annual Revenues, 2014 – 2020 (INR Billion)
Figure 7.29 Nectar Lifesciences: Service Portfolio
Figure 7.30 Syngene: Annual Revenues, 2014 – 2020 (INR Billion)
Figure 7.31 Syngene: Service Portfolio
Figure 7.32 WuXi AppTec: Annual Revenues, 2015 – Q1 2021 (RMB Billion)
Figure 7.33 WuXi AppTec: Revenues by Business Segment, 2020 (RMB Billion)
Figure 7.34 WuXi AppTec: Service Portfolio
Figure 7.35 STA Pharmaceuticals (A subsidiary of WuXi AppTec): Service Portfolio
Figure 8.1 Make versus Buy Decision Making Framework
Figure 8.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 9.1 Mergers and Acquisitions: Cumulative Year-wise Distribution, 2017-2021
Figure 9.2 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 9.3 Acquisitions: Distribution by Type of Acquisition
Figure 9.4 Mergers and Acquisitions: Distribution by Focus Area
Figure 9.5 Mergers and Acquisitions: Distribution by Type of Business Segment
Figure 9.6 Mergers and Acquisitions: Distribution by Type of Service(s) Offered
Figure 9.7 Mergers and Acquisitions: Distribution by Scale of Operation
Figure 9.8 Mergers and Acquisitions: Distribution by Geography
Figure 9.9 Mergers and Acquisitions: Distribution by Location of Manufacturing Facility
Figure 9.10 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 9.11 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 9.12 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 9.13 Key Acquisitions: Distribution by Deal Multiples
Figure 10.1 Recent Expansions: Cumulative Year-wise Distribution, 2017-2021
Figure 10.2 Recent Expansions: Distribution by Purpose of Expansion
Figure 10.3 Recent Expansions: Distribution by Year and Purpose of Expansion
Figure 10.4 Recent Expansions: Distribution by Type of Business Segment
Figure 10.5 Recent Expansions: Distribution by Type of Molecule
Figure 10.6 Recent Expansions: Distribution by Type of Service(s) Offered
Figure 10.7 Recent Expansions: Distribution by Scale of Operation
Figure 10.8 Recent Expansions: Distribution by Capital Invested (USD Million)
Figure 10.9 Recent Expansions: Distribution by Location of Headquarters
Figure 10.10 Recent Expansions: Distribution by Purpose of Expansion and Location of Headquarters
Figure 10.11 Recent Expansions: Distribution by Location of Manufacturing Facility
Figure 10.12 Most Active Players: Distribution by Number of Expansion Initiatives
Figure 11.1 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Size of CMOs (Sample Data Set)
Figure 11.2 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Size of CMOs
Figure 11.3 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Scale of Operation
Figure 11.4 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Location of Headquarters
Figure 11.5 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Location of Manufacturing Facilities (Region-wise)
Figure 11.6 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 12.1 Overall Annual Demand for Small Molecule APIs, 2021-2030 (Metric Ton)
Figure 12.2 Demand for Small Molecule APIs in North America, 2021-2030 (Metric Ton)
Figure 12.3 Demand for Small Molecule APIs in Europe, 2021-2030 (Metric Ton)
Figure 12.4 Demand for Small Molecule APIs in Asia-Pacific and Rest of the World, 2021-2030 (Metric Ton)
Figure 12.5 Demand for Small Molecule APIs at Clinical Scale, 2021-2030 (Metric Ton)
Figure 12.6 Demand for Small Molecule APIs at Commercial Scale, 2021-2030 (Metric Ton)
Figure 13.1 Global Pharmaceutical Contract Manufacturing Market, 2021-2030 (USD Billion)
Figure 13.2 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Business Segment (USD Billion)
Figure 13.3 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of API Manufactured (USD Billion)
Figure 13.4 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of FDF Offered (USD Billion)
Figure 13.5 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Scale of Operation (USD Billion)
Figure 13.6 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of Packaging Form (USD Billion)
Figure 13.7 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of End-User (USD Billion)
Figure 13.8 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Geography (USD Billion)
Figure 13.9 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030 (USD Billion)
Figure 13.10 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Business Segment (USD Billion)
Figure 13.11 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Figure 13.12 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Figure 13.13 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.14 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Figure 13.15 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of End-User (USD Billion)
Figure 13.16 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030 (USD Billion)
Figure 13.17 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Business Segment (USD Billion)
Figure 13.18 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Figure 13.19 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Figure 13.20 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.21 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Figure 13.22 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of End-User (USD Billion)
Figure 13.23 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030 (USD Billion)
Figure 13.24 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Business Segment (USD Billion)
Figure 13.25 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Figure 13.26 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Figure 13.27 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.28 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Figure 13.29 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of End-User (USD Billion)
Figure 13.30 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030 (USD Billion)
Figure 13.31 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Business Segment (USD Billion)
Figure 13.32 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Figure 13.33 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Figure 13.34 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.35 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Figure 13.36 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of End-User (USD Billion)
Figure 13.37 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030 (USD Billion)
Figure 13.38 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Business Segment (USD Billion)
Figure 13.39 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Figure 13.40 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Figure 13.41 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.42 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Figure 13.43 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of End-User (USD Billion)
Figure 14.1 Integrated Service Providers Heat Map Analysis: Distribution by Year of Establishment, Company Size and Geography
Figure 14.2 Pharmaceutical CMOs: Geographical Distribution by Location of Manufacturing Facilities
Figure 14.3 Pharmaceutical CMOs: Distribution by Business Segment, Company Size and Geography
Figure 15.1 Pharmaceutical Contract Manufacturing SWOT Analysis: Overview
Figure 15.2 Pharmaceutical Contract Manufacturing SWOT Analysis: Strengths
Figure 15.3 Pharmaceutical Contract Manufacturing SWOT Analysis: Weaknesses
Figure 15.4 Pharmaceutical Contract Manufacturing SWOT Analysis: Opportunities
Figure 15.5 Pharmaceutical Contract Manufacturing SWOT Analysis: Threats
Figure 15.6 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 16.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2020
Figure 16.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Process
Figure 17.1 Concluding Remarks: Summary of Market Landscape
Figure 17.2 Concluding Remarks: Summary of Mergers and Acquisitions
Figure 17.3 Concluding Remarks: Summary of Recent Expansions
Figure 17.4 Concluding Remarks: Summary of Capacity Analysis
Figure 17.5 Concluding Remarks: Summary of Demand Analysis
Figure 17.6 Concluding Remarks: Summary of Market Sizing and Opportunity Analysis

List Of Tables

Table 4.1 Comparison of FDA Quality Agreement and EMA cGMP guidelines
Table 4.2 Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
Table 4.3 Key Regulatory Authorities: Comparison of NDA Approval Characteristics
Table 5.1 List of Pharmaceutical CMOs
Table 5.2 Pharmaceutical CMOs: Information on Type of Business Segment and Type of API Manufactured
Table 5.3 Pharmaceutical CMOs: Information on Type of FDF Offered and Type of Molecule
Table 5.4 Pharmaceutical CMOs: Information on Type of Service(s) Offered
Table 5.5 Pharmaceutical CMOs: Information on Type of Primary Packaging Form Offered
Table 5.6 Pharmaceutical CMOs: Information on Scale of Operation
Table 7.1 Pharmaceutical Contract Manufacturing: List of Companies Profiled
Table 7.2 AMRI: Company Snapshot
Table 7.3 AMRI: Manufacturing Facilities
Table 7.4 AMRI: Sterile Manufacturing Facilities
Table 7.5 AMRI: Recent Developments and Future Outlook
Table 7.6 Altasciences: Company Snapshot
Table 7.7 Altasciences: Recent Developments and Future Outlook
Table 7.8 Cambrex: Company Snapshot
Table 7.9 Catalent: Company Snapshot
Table 7.10 DPT Laboratories: Company Snapshot
Table 7.11 DPT Laboratories: Manufacturing Facilities
Table 7.12 Thermo Fisher Scientific: Company Snapshot
Table 7.13 Thermo Fisher Scientific: Manufacturing Facilities
Table 7.14 Aenova Group: Company Snapshot
Table 7.15 Aenova Group: Manufacturing Facilities
Table 7.16 Almac Group: Company Snapshot
Table 7.17 Corden Pharma: Company Snapshot
Table 7.18 Corden Pharma: Manufacturing Facilities
Table 7.19 Fresenius Kabi: Company Snapshot
Table 7.20 Fresenius Kabi: Manufacturing Facilities
Table 7.21 Fresenius Kabi: Packaging Capabilities
Table 7.22 Glatt: Company Snapshot
Table 7.23 Glatt: Manufacturing Facilities
Table 7.24 Hovione: Company Snapshot
Table 7.25 Hovione: Manufacturing Facilities
Table 7.26 Hovione: Recent Developments and Future Outlook
Table 7.27 Recipharm: Company Snapshot
Table 7.28 Recipharm: Manufacturing Facilities
Table 7.29 Recipharm: Recent Developments and Future Outlook
Table 7.30 Siegfried: Company Snapshot
Table 7.31 Siegfried: Manufacturing Facilities
Table 7.32 Siegfried: Recent Developments and Future Outlook
Table 7.33 CMIC Group: Company Snapshot
Table 7.34 Nectar Lifesciences: Company Snapshot
Table 7.35 Nectar Lifesciences: Manufacturing Facilities
Table 7.36 Syngene: Company Snapshot
Table 7.37 Syngene: Manufacturing Facilities
Table 7.38 WuXi AppTec: Company Snapshot
Table 7.39 WuXi AppTec: Manufacturing Facilities
Table 7.40 WuXi AppTec: Recent Developments and Future Outlook
Table 9.1 Pharmaceutical Contract Manufacturing: List of Mergers and Acquisitions
Table 10.1 Pharmaceutical Contract Manufacturing: List of Recent Expansions
Table 11.1 Pharmaceutical Contract Manufacturing Installed Capacity: Average Capacity by Size of CMOs (Sample Data Set)
Table 11.2 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 13.1 Ajinomoto Althea: Key Highlights
Table 13.2 Bachem: Key Highlights
Table 13.3 Batavia Biosciences: Key Highlights
Table 13.4 CiVentiChem: Key Highlights
Table 13.5 Helsinn Group: Key Highlights
Table 13.6 Novasep: Key Highlights
Table 13.7 Polymun Scientific: Key Highlights
Table 13.8 Rentschler Biopharma: Key Highlights
Table 13.9 Sovereign Pharma: Key Highlights
Table 13.10 WACKER Biotech: Key Highlights
Table 13.11 Wavelength Pharmaceuticals: Key Highlights
Table 19.1 Regulatory Landscape for Pharmaceutical CMOs: Distribution by Types of Regulatory Authorities
Table 19.2 Pharmaceutical CMOs: Distribution by Year of Establishment
Table 19.3 Pharmaceutical CMOs: Distribution by Company Size
Table 19.4 Pharmaceutical CMOs: Distribution by Location of Headquarters
Table 19.5 Pharmaceutical CMOs: Distribution by Type of Business Segment
Table 19.6 Pharmaceutical CMOs: Distribution by Type of API Manufactured
Table 19.7 Pharmaceutical CMOs: Distribution by Type of FDF Offered
Table 19.8 Pharmaceutical CMOs: Distribution by Type of Molecule
Table 19.9 Pharmaceutical CMOs: Distribution by Type of Service(s) Offered
Table 19.10 Pharmaceutical CMOs: Distribution by Type of Primary Packaging Offered
Table 19.11 Pharmaceutical CMOs: Distribution by Scale of Operation
Table 19.12 Pharmaceutical CMOs: Distribution by Location of Headquarters and Type of Service(s) Offered
Table 19.13 Pharmaceutical CMOs: Distribution by Type of Business Segment and Type of Service(s) Offered
Table 19.14 Pharmaceutical CMOs: Distribution by Type of Service(s) Offered and Scale of Operation
Table 19.15 Pharmaceutical CMOs: Distribution of Manufacturing Facilities in North America
Table 19.16 Pharmaceutical CMOs: Distribution of Manufacturing Facilities in Europe
Table 19.17 Pharmaceutical CMOs: Distribution of Manufacturing Facilities in Asia-Pacific and Rest of the World
Table 19.18 Regional Distribution of Pharmaceutical Contract Manufacturing Facilities in North America
Table 19.19 Regional Distribution of Pharmaceutical Contract Manufacturing Facilities in Europe
Table 19.20 Regional Distribution of Pharmaceutical Contract Manufacturing Facilities in Asia-Pacific and Rest of the World
Table 19.21 Catalent: Annual Revenues, 2014-2020 (USD Million)
Table 19.22 Thermo Fisher Scientific: Annual Revenues, 2014-2020 (USD Billion)
Table 19.23 Thermo Fisher Scientific: Revenues by Business Segments, 2020 (USD Billion)
Table 19.24 Aenova Group: Annual Revenues 2017-2019 (EUR Million)
Table 19.25 Fresenius Kabi: Annual Revenues, 2014-2020 (EUR Million)
Table 19.26 Fresenius Kabi: Revenues by Product Segments, 2020 (EUR Million)
Table 19.27 Recipharm: Annual Revenues, 2014-2020 (SEK Million)
Table 19.28 Recipharm: Revenues by Business Segment, 2020 (SEK Million)
Table 19.29 Siegfried: Annual Revenues, 2013-2020 (CHF Million)
Table 19.30 Siegfried: Revenues by Product Segments, 2020 (CHF Million)
Table 19.31 CMIC Group: Annual Revenues, 2014 - H1 2021 (JPY Billion)
Table 19.32 CMIC Group: Revenues by Business Segment, 2020 (JPY Billion)
Table 19.33 Nectar Lifesciences: Annual Revenues, 2014 – 2020 (INR Billion)
Table 19.34 Syngene: Annual Revenues, 2014 – 2020 (INR Billion)
Table 19.35 WuXi AppTec: Annual Revenues, 2015 – Q1 2021 (RMB Billion)
Table 19.36 WuXi AppTec: Revenues by Business Segment, 2020 (RMB Billion)
Table 19.37 Mergers and Acquisitions: Cumulative Year-wise Distribution, 2017-2021 (till May)
Table 19.38 Mergers and Acquisitions: Distribution by Type of Agreement
Table 19.39 Acquisitions: Distribution by Type of Acquisition
Table 19.40 Mergers and Acquisitions: Distribution by Focus Area
Table 19.41 Mergers and Acquisitions: Distribution by Type of Business Segment
Table 19.42 Mergers and Acquisitions: Distribution by Type of Service(s) Offered
Table 19.43 Mergers and Acquisitions: Distribution by Scale of Operation
Table 19.44 Mergers and Acquisitions: Distribution by Geography
Table 19.45 Mergers and Acquisitions: Distribution by Location of Manufacturing Facility
Table 19.46 Most Active Acquirers: Distribution by Number of Acquisitions
Table 19.47 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 19.48 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 19.49 Key Acquisitions: Distribution by Deal Multiples
Table 19.50 Recent Expansions: Cumulative Year-wise Distribution, 2017-2021 (till May)
Table 19.51 Recent Expansions: Distribution by Purpose of Expansion
Table 19.52 Recent Expansions: Distribution by Year and Purpose of Expansion
Table 19.53 Recent Expansions: Distribution by Type of Business Segment
Table 19.54 Recent Expansions: Distribution by Type of Molecule
Table 19.55 Recent Expansions: Distribution by Type of Service(s) Offered
Table 19.56 Recent Expansions: Distribution by Scale of Operation
Table 19.57 Recent Expansions: Distribution by Capital Invested (USD Million)
Table 19.58 Recent Expansions: Distribution by Location of Headquarters
Table 19.59 Recent Expansions: Distribution by Purpose of Expansion and Location of Headquarters
Table 19.60 Recent Expansions: Distribution by Location of Manufacturing Facility
Table 19.61 Most Active Players: Distribution by Number of Expansion Initiatives
Table 19.62 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Size of CMOs (Sample Data Set)
Table 19.63 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Size of CMOs
Table 19.64 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Scale of Operation
Table 19.65 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Location of Headquarters
Table 19.66 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Location of Manufacturing Facilities (Region-wise)
Table 19.67 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 19.68 Overall Annual Demand for Small Molecule APIs, 2021-2030 (Metric Ton)
Table 19.69 Demand for Small Molecule APIs in North America, 2021-2030 (Metric Ton)
Table 19.70 Demand for Small Molecule APIs in Europe, 2021-2030 (Metric Ton)
Table 19.71 Demand for Small Molecule APIs in Asia-Pacific and Rest of the World, 2021-2030 (Metric Ton)
Table 19.72 Demand for Small Molecule APIs at Clinical Scale, 2021-2030 (Metric Ton)
Table 19.73 Demand for Small Molecule APIs at Commercial Scale, 2021-2030 (Metric Ton)
Table 19.74 Global Pharmaceutical Contract Manufacturing Market, 2021-2030 (USD Billion)
Table 19.75 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Business Segment (USD Billion)
Table 19.76 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of API Manufactured (USD Billion)
Table 19.77 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of FDF Offered (USD Billion)
Table 19.78 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Scale of Operation (USD Billion)
Table 19.79 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of Packaging Form (USD Billion)
Table 19.80 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of End-User (USD Billion)
Table 19.81 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Geography (USD Billion)
Table 19.82 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030 (USD Billion)
Table 19.83 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Business Segment (USD Billion)
Table 19.84 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Table 19.85 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Table 19.86 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Scale of Operation (USD Billion)
Table 19.87 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Table 19.88 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of End-User (USD Billion)
Table 19.89 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030 (USD Billion)
Table 19.90 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Business Segment (USD Billion)
Table 19.91 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Table 19.92 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Table 19.93 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Scale of Operation (USD Billion)
Table 19.94 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Table 19.95 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of End-User (USD Billion)
Table 19.96 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030 (USD Billion)
Table 19.97 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Business Segment (USD Billion)
Table 19.98 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Table 19.99 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Table 19.100 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Billion)
Table 19.101 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Table 19.102 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of End-User (USD Billion)
Table 19.103 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030 (USD Billion)
Table 19.104 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Business Segment (USD Billion)
Table 19.105 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Table 19.106 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Table 19.107 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030:Distribution by Scale of Operation (USD Billion)
Table 19.108 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Table 19.109 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of End-User (USD Billion)
Table 19.110 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030 (USD Billion)
Table 19.111 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Business Segment (USD Billion)
Table 19.112 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Table 19.113 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Table 19.114 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Scale of Operation (USD Billion)
Table 19.115 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Table 19.116 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of End-User (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. A. S. Joshi & Company
  2. Aarti Industries
  3. AbbVie
  4. Abiogen Pharma
  5. Accra Pac
  6. ACIC Pharmaceuticals
  7. Acino
  8. Acme Group
  9. Acorda Therapeutics
  10. ACS Dobfar
  11. Actiza Pharmaceutical
  12. Adare Pharmaceuticals
  13. Admac Formulations
  14. Advent International
  15. Aenova
  16. Afton Scientific
  17. AGIC Capital
  18. Agno Pharma
  19. Aiomedic Pharmaceuticals
  20. AiPing Pharmaceutical
  21. Ajinomoto Bio-Pharma Services
  22. Akorn
  23. Akrikhin
  24. Akums Drugs & Pharmaceuticals
  25. Albatross Pharmaceuticals
  26. Albemarle
  27. AlbyPharma
  28. Alcami
  29. Alembic Pharmaceuticals
  30. Alkem Laboratories
  31. Alkermes
  32. Allchem Laboratories
  33. Almac
  34. Almelo
  35. Alps Pharmaceutical
  36. Altasciences
  37. Althea Pharma
  38. Alvogen
  39. Amanta Healthcare
  40. AmbioPharm
  41. American Regent
  42. Ami Lifesciences
  43. Amman Pharmaceutical Industries
  44. Amneal Pharmaceuticals
  45. Amoli Organics
  46. AMPAC Fine Chemicals
  47. AMRI
  48. Angelini Pharma
  49. Anhui Biochem United Pharmaceutical
  50. ANI Pharmaceuticals
  51. Ankur Drugs and Pharma
  52. Anqiu Lu'an Pharmaceutical
  53. Anugraha Chemicals
  54. ANVI Pharma
  55. API Co. Ltd
  56. API Pharma Tech
  57. Apicore
  58. Apiscent Laboratories (acquired by Kingchem Life Sciences)
  59. APL Pharma Specials
  60. Appco Pharma
  61. Aptuit
  62. Arbro Pharmaceuticals
  63. Arch Pharmalabs
  64. Arcinova
  65. Ardena
  66. Arevipharma
  67. Argonaut
  68. Aristo Pharma
  69. Arvincare
  70. Aspen
  71. Aspen Pharmacare
  72. Aster Pharma
  73. Asymchem
  74. Atra Pharmaceuticals
  75. Aurigene Pharmaceutical Services
  76. Aurobindo Pharma
  77. Austar Pharma
  78. Avara Pharmaceutical Services
  79. Avra Laboratories
  80. AVVA Pharmaceuticals
  81. Axa Parenterals
  82. Baccinex
  83. Bachem 
  84. Bal Pharma
  85. Bankyo Pharmaceutical
  86. Batterjee Pharma
  87. Bausch Health 
  88. Baxter
  89. Baxter BioPharma Solutions
  90. BCN Peptides
  91. BDR Pharmaceuticals
  92. Belco Pharma
  93. Bellwyck Pharma Services (acquired by PCI Pharma Services)
  94. Beltapharm
  95. Bennet Pharmaceuticals
  96. BePharBel
  97. Beximco Pharmaceuticals
  98. BINEX
  99. Biological E
  100. Biophore
  101. Bioserv
  102. Biosint
  103. Bio-Synthesis
  104. BioVectra
  105. Biozoc
  106. Bluepharma
  107. Bonarum Pharma
  108. Bora Pharmaceuticals
  109. Brassica Pharma
  110. Bridgepoint 
  111. Bristol Laboratories
  112. Broad Pharmaceutical
  113. Bushu Pharma
  114. Cadila Pharmaceuticals
  115. Calyx Chemicals & Pharmaceuticals
  116. Cambrex
  117. Canonpharma
  118. Caplin Point Laboratories
  119. Capsugel
  120. CARBOGEN AMCIS
  121. Carlyle Group
  122. Cascade Chemistry
  123. Catalent
  124. Cayman Chemical
  125. Cenexi
  126. Centaur Pharmaceuticals
  127. Century Pharmaceuticals
  128. Cerbios-Pharma
  129. Chartwell Pharmaceuticals
  130. ChemCon
  131. ChemConnection
  132. Chemigran
  133. ChemPacific
  134. Chiral Biosciences
  135. Chirogate International
  136. Chongqing Huapont Pharmaceutical
  137. Chromo Laboratories
  138. Chunghwa Chemical Synthesis & Biotech
  139. Ciron Drugs
  140. CiVentiChem
  141. CJ HealthCare
  142. Claris Injectables (acquired by Baxter)
  143. Clearsynth
  144. CMIC Group
  145. Coating Place
  146. Concord Drugs
  147. Confab Laboratories
  148. Consort Medical
  149. Contract Coating
  150. Contract Pharmacal
  151. Copperhead Chemical Company
  152. CordenPharma
  153. CoreRx
  154. CPC Scientific
  155. Contract Pharmaceuticals Limited (CPL)
  156. Crenza Pharmaceuticals
  157. Cris Pharma
  158. Crown Laboratories
  159. CTX Lifesciences
  160. Daiichi Sankyo
  161. Daito Pharmaceutical
  162. Dalton Pharma Services
  163. DBK Pharmaceutical
  164. Dearborn Partners
  165. Dechra Pharmaceuticals
  166. Delmar Chemicals
  167. Delpharm
  168. Delta Laboratories
  169. Dermopartners
  170. DEVA 
  171. Dhanuka Labortories
  172. Dhruv Life Sciences
  173. Dipharma 
  174. Dishman Biotech (acquired by CARBOGEN AMCIS)
  175. DIVERCHIM
  176. Divi's Laboratories
  177. DM Pharma Marketing
  178. Dottikon Exclusive Synthesis
  179. Douglas Pharmaceuticals
  180. DPT Laboratories
  181. Dr. Pradeep Reddy's Laboratories
  182. Dupen Laboratories
  183. Dwarkesh Pharmaceuticals
  184. EirGen Pharma
  185. E.L. Laboratories
  186. Elfin
  187. Elite Pharmaceuticals
  188. Embio
  189. Emcure Pharmaceuticals
  190. Emergent BioSolutions
  191. Eminent Healthcare
  192. Enaltec
  193. Entema Laboratories
  194. Entod Pharmaceuticals
  195. Epic Pharma
  196. Ercros
  197. Eriochem
  198. Erregierre
  199. Esteve 
  200. Ethypharm
  201. Eurofins
  202. Euro-Med Laboratories
  203. EVER Pharma
  204. Evonik Industries
  205. Evotec
  206. Exela Pharma Sciences
  207. FAMAR
  208. Fareva
  209. Farmak
  210. Farmasierra
  211. Farmhispania Group
  212. Farmigea
  213. Fermion
  214. Ferndale laboratories
  215. FineTech Pharmaceuticals
  216. Flamingo Pharmaceuticals
  217. Flamma
  218. Fleming Laboratories
  219. Fresenius Kabi
  220. FTF Pharma
  221. Fuji Chemical
  222. Fuji Pharma
  223. Fujifilm RI Pharma
  224. Fujimoto Chemicals
  225. Future Pak
  226. Galentic Pharma
  227. G.D Pharmaceuticals
  228. Gebro Pharma
  229. Gedeon Richter
  230. General Atlantic
  231. Getz Pharma
  232. GHO Capital
  233. Gland Pharma
  234. Glatt
  235. GlaxoSmithKline
  236. Glenmark Pharmaceuticals
  237. Globela Pharma
  238. Glochem Industries
  239. GP Pharm
  240. Grand River Aseptic Manufacturing
  241. Granules India
  242. Grindeks
  243. Groupe PARIMA
  244. Grünenthal
  245. Guardian Drug Company
  246. GVK BIO
  247. Halo Pharma
  248. Handok
  249. Hanford Pharmaceuticals
  250. Hangzhou Hysen Pharma
  251. Hanuchem Laboratories
  252. HBM Pharma
  253. Health Biotech
  254. Healthy Life Pharma
  255. Helios Pharmaceuticals
  256. Helsinn Group
  257. Hetero Drugs
  258. H.I.G Capital
  259. Hikal
  260. Hovione
  261. HP Toride Pharma
  262. Hritik Chemicals
  263. Hubei Biocause Pharmaceutical
  264. Huvepharma
  265. ICROM
  266. IDT Australia
  267. Impopharma (acquired by Rubicon Research)
  268. Indena
  269. Indoco Remedies
  270. Ind-Swift Laboratories
  271. Ingenus Pharmaceuticals
  272. Innova Captab
  273. Intas Pharmaceuticals
  274. Interquim
  275. Ipca Laboratories
  276. i-Pharmaceuticals
  277. Isochem (acquired by PMC Group)
  278. Iwaki Seiyaku Sakura Factory
  279. JB Chemicals and Pharmaceutical
  280. Jay Chemicals
  281. Jadran Galenski Laboratory (JGL)
  282. J-Star Research
  283. Jubilant Biosys
  284. Kalexsyn
  285. Kamat Pharmatech
  286. Katsura Chemical
  287. Kekule Pharma
  288. Kemwell Biopharma
  289. Kilitch Drugs
  290. Kingchem Life Sciences
  291. Kohlberg & Company
  292. Kokando
  293. Kolmar
  294. Kongo Chemical
  295. Korten
  296. KP Pharmaceutical Technology
  297. Krebs Biochemicals
  298. Kryptochem Medicament
  299. Kyoto Pharmaceutical
  300. Kyowa Pharma Chemical 
  301. Laboratorios Farmacéuticos ROVI
  302. Laboratorios Inibsa
  303. Salvat
  304. Lameplast
  305. Lamplast
  306. Laurus Labs
  307. Lebsa
  308. Lenus Lifecare
  309. LGM Pharma
  310. Lifekyor Pharmaceuticals
  311. Lloyd Laboratories
  312. LOBA Feinchemie
  313. Logos Pharma
  314. Lomapharm
  315. Lonza
  316. Lotus Pharma
  317. LSNE
  318. Lubrizol Life Science
  319. Luitpold Pharmaceuticals
  320. Lyne Laboratories
  321. M2i
  322. Macter 
  323. Madras Pharmaceuticals
  324. Maiva Pharma
  325. Makcur Laboratories
  326. Malladi Drugs & Pharmaceuticals
  327. Matreya
  328. Maxtar Bio Genics
  329. McGuff Pharmaceuticals
  330. Medical Product Laboratories
  331. Medichem
  332. Medilux Laboratories
  333. Mediwin Pharmaceuticals
  334. MedPharm
  335. Mehta API
  336. Menadiona
  337. Symeres
  338. Metrics Contract Services
  339. Metrochem API
  340. Micro Labs
  341. Micro-Sphere
  342. Mikart
  343. MINAKEM
  344. Mipharm
  345. MSN Laboratories
  346. Multi Packaging Solutions
  347. Multi-Pack Solutions
  348. Murty Pharmaceuticals
  349. Nagase Medicals
  350. Nakoda Chemicals
  351. Nanjing Pharmatechs
  352. Natco Pharma
  353. Nautic Partners
  354. Nectar Lifesciences
  355. Neiss Labs
  356. Nephron Pharmaceutuicals
  357. NerPharma
  358. Neuland Laboratories
  359. Nexgen Pharma (acquired by LGM Pharma)
  360. Nextar Chempharma Solutions
  361. NextPharma
  362. Nippon Rika Technologies
  363. Nipro Pharma
  364. Nitto Avecia
  365. Nivon Specialties
  366. Norac Pharma
  367. Norchim
  368. Novacap
  369. NovaQuest
  370. Novartis
  371. Novasep
  372. Novo Holdings
  373. Nutragen Pharma
  374. Nutraplus India
  375. Nvron Life Science
  376. Oakwood Labs
  377. Oasis Laboratories
  378. Oceanic Pharmachem
  379. Olainfarm
  380. Olic (Thailand) 
  381. Olon
  382. Oman Pharmaceutical Products
  383. Oncotec Pharma Produktion
  384. Orbis Biosciences
  385. Orchid Pharma
  386. Orient Pharma
  387. Orion 
  388. Orofino Pharmaceuticals
  389. Otsuka Pharmaceutical
  390. Panacea Biotec
  391. PannonPharma
  392. Parabolic Drugs
  393. Patheon
  394. PCI Pharma Services
  395. Pegasus Farmaco
  396. Penmix
  397. Perrigo
  398. Pfizer
  399. Pfizer CentreOne
  400. Pharma Stulln
  401. PharmAgra Labs
  402. Pharma-Q
  403. Pharmascience
  404. Pharmasol
  405. PharmaSynth
  406. PharmaZell
  407. Pharmed Healthcare
  408. Pharmer
  409. Phekolong Pharmaceuticals (Laurus Labs)
  410. Phytex Australia
  411. Phyton Biotech
  412. Pidolma Healthcare
  413. Pharmaceutical Institute of India (Pii)
  414. Pillar5 Pharma
  415. PIQ-Pharma
  416. Piramal Pharma
  417. PiSA Farmaceutica
  418. Pisgah Labs (acquired by Ipca Laboratories)
  419. i Group
  420. PMRS
  421. Polfa Tarchomin
  422. Polpharma
  423. Poly Pharmaceuticals
  424. PolyPeptide
  425. Porton Fine Chemicals
  426. Permira
  427. PrimaPharma
  428. Prisha Healthcare
  429. Priyans Drugs
  430. Procaps
  431. Procos
  432. Pyramid Pharma
  433. Qualiphar-Gifrer
  434. Quality Chemical Laboratories
  435. Quay Pharmaceuticals
  436. Que Pharma
  437. Quotient Sciences
  438. Radico Remedies
  439. Rafarm
  440. Raybow PharmScience
  441. Recipharm
  442. Redwing Pharma
  443. Regis Technologies
  444. Remington Pharmaceuticals
  445. Olon Ricerca Biosciences
  446. Ritedose
  447. Rivopharm
  448. RL Fine Chem
  449. Robinson Brothers
  450. Rommelag
  451. Rompharm
  452. Rottendorf Pharma
  453. Rubicon Research
  454. Rusan Pharma
  455. S M Pharmaceuticals
  456. Sai Life Sciences
  457. Sandoz
  458. Sanico
  459. Sannova Biotech
  460. Sanochemia Pharmazeutika
  461. Santen Pharmaceutical
  462. Sanwa Kagaku Kenkyusho
  463. Sarvodaya Drugs and Pharmaceuticals 
  464. Sarvotham Care
  465. Sato Yakuhin Kogyo
  466. SAVA Healthcare
  467. Savior Lifetec
  468. SCI Pharmatech
  469. ScinoPharm
  470. Seacross Pharmaceuticals
  471. Seikagaku 
  472. Sekisui Medical
  473. Selvok Pharmaceutical
  474. Sentiss Pharma
  475. Seqens
  476. Shandong Xinhua Pharmaceutical
  477. Sharon Bio-Medicine
  478. Shilpa Medicare
  479. Siegfried
  480. Sigmapharma Laboratories
  481. Sinopharm
  482. Sirio Pharma
  483. SK biotek
  484. SK Holdings
  485. Smruthi Organics 
  486. SMS Pharmaceuticals
  487. Societa Italiana Medicinali Scandicci
  488. Softgel Healthcare
  489. Solara Active Pharma Sciences
  490. Solopharm
  491. Sovereign Pharmaceuticals
  492. SPC Lifesciences
  493. Square Pharmaceuticals
  494. Stason Pharmaceutical
  495. Stelis Biopharma
  496. Stericon Pharma
  497. Sterling Pharma Solutions
  498. Sterling Pharmaceuticals
  499. Sunrise Pharmaceutical
  500. Sunways
  501. Supriya LifeScience
  502. Suven Life Sciences
  503. Swiss Pharma
  504. Symed Labs
  505. Synbias Pharma
  506. Syncom Healthcare
  507. Syngene
  508. Synthokem Labs
  509. Sypharma
  510. Syntegon
  511. Tahira Industries
  512. Tai Heng Industry
  513. Taiyo Pharma Tech
  514. Tatchempharmpreparaty
  515. Tedor Pharma
  516. Teika Pharmaceutical
  517. Tekni-Plex
  518. Teligent
  519. Teva Pharmaceuticals
  520. Theon Pharmaceuticals
  521. Thermo Fisher Scientific
  522. Titan Pharmaceuticals
  523. Toa Pharmaceutical
  524. Tolmar
  525. Torrent Pharmaceuticals
  526. FUJIFILM Toyama Chemical
  527. TriPharm Services (acquired by Alcami)
  528. Trugen Pharma
  529. Tyger Scientific
  530. UBE Industries
  531. Ultratech India
  532. Unibiotech Formulations
  533. Unichem Laboratories
  534. Unimark Remedies
  535. Unison Chemical Works
  536. UPM Pharmaceutical
  537. Uquifa 
  538. Ursapharm Arzneimittel
  539. US Pharma Lab
  540. USV
  541. Vanamali Organics (acquired by Wavelength Pharmaceuticals)
  542. Vetter Pharma
  543. Vinkem Labs
  544. Vital Healthcare 
  545. VUAB Pharma (SAFICHEM)
  546. Wanbury
  547. Wavelength Pharmaceutical
  548. WCCT Global
  549. WDPrx- Woodfield Pharmaceutical
  550. WellSpring Pharmaceuticals
  551. West Pharmaceutical Services
  552. WestRock
  553. Wilmington PharmaTech
  554. Windlas Healthcare
  555. Wintac
  556. Wisdom Pharmaceuticals
  557. Wockhardt
  558. WuXi AppTec
  559. Xellia Pharmaceuticals
  560. Xi'an Lijun Pharmaceutical 
  561. Xttrium Laboratories
  562. YaoPharma
  563. Yash Pharma Laboratories
  564. Yegna Manojavam Drugs and Chemicals (acquired by PMC Group)
  565. Yuhan
  566. Yung Zip Chemical
  567. Zach Systems (Zambon)
  568. ZCL Chemicals (acquired by Advent International)
  569. Zenith Healthcare
  570. Zenlabs
  571. ZheJiang Apeloa JiaYuan Pharmaceutical
  572. Zhejiang Changming Pharmaceutical
  573. Zhejiang Cheng Yi Pharmaceutical
  574. Zhejiang Excel Pharmaceutical
  575. Zhejiang Hisun Pharmaceutical
  576. Zhejiang Huahai Pharmaceutical

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com